nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

01.10.2011 | Article

Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy

verfasst von: M. Guzmán-Fulgencio, J. Berenguer, M. García-Álvarez, D. Micheloud, J. C. López, J. Cosín, I. Fernández de Castro, P. Catalán, P. Miralles, S. Resino

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 10/2011

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate the influence of clinical and epidemiological characteristics of 183 HIV/HCV coinfected patients and HCV clearance after antiviral treatment on serum sFas and sFasL levels. Thirty out of 183 patients underwent HCV antiviral therapy with IFN-α + RBV for a duration of 48 weeks. HCV genotype 1 and homeostasis model assessment for insulin resistance (HOMA-IR) had a significant positive relationship, and CD4+/μL had a significant negative relationship with sFas (R-square = 0.582; p < 0.001) and sFasL (R-square = 0.216; p < 0.001) in multivariate linear regression analysis. HCV genotype 1 was the only significant variable associated with the sFas/sFasL ratio (R-square = 0.201; p < 0.001). sFas and sFasL levels had positive significant correlations with serum sICAM-1, sVCAM-1, and HOMA levels (p < 0.05). Among patients on IFN-α + RBV therapy, 15 patients showed a sustained virologic response (SVR), while 15 patients were non-responders (NR). Patients with SVR had significant decreases in sFas (p = 0.008) and sFas/sFasL ratio (p = 0.002), while non-responders had a significant increase in sFasL values (p = 0.013). In conclusion, HCV genotype 1, high HOMA, and low CD4+/μL were associated with high serum levels of sFas and sFasL, which indicate higher levels of inflammation and, possibly, increased cardiovascular risk. Moreover, response to HCV antiviral therapy is known to reduce inflammation.

Strasser A, Jost PJ, Nagata S (2009) The many roles of FAS receptor signaling in the immune system. Immunity 30(2):180–192PubMedCrossRef

Xerri L, Devilard E, Hassoun J, Mawas C, Birg F (1997) Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol 50(2):87–91PubMedCrossRef

Ferguson TA, Griffith TS (2006) A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol Rev 213:228–238PubMedCrossRef

Lee SH, Shin MS, Lee JY, Park WS, Kim SY, Jang JJ, Dong SM, Na EY, Kim CS, Kim SH, Yoo NJ (1999) In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas. J Pathol 188(2):207–212PubMedCrossRef

Nonomura N, Nishimura K, Ono Y, Fukui T, Harada Y, Takaha N, Takahara S, Okuyama A (2000) Soluble Fas in serum from patients with renal cell carcinoma. Urology 55(1):151–155PubMedCrossRef

Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H (1995) Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182(6):1777–1783PubMedCrossRef

Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187(8):1205–1213PubMedCrossRef

Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66(2):233–243PubMedCrossRef

Suda T, Nagata S (1994) Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 179(3):873–879PubMedCrossRef

10.

Pol S, Soriano V (2008) Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 47(1):94–101PubMedCrossRef

11.

Poonia B, Pauza CD, Salvato MS (2009) Role of the Fas/FasL pathway in HIV or SIV disease. Retrovirology 6:91PubMedCrossRef

12.

Raghuraman S, Abraham P, Daniel HD, Ramakrishna BS, Sridharan G (2005) Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection. J Clin Virol 34(1):63–70PubMedCrossRef

13.

Bortolami M, Kotsafti A, Cardin R, Farinati F (2008) Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat 15(7):515–522PubMedCrossRef

14.

Hosaka N, Oyaizu N, Than S, Pahwa S (2000) Correlation of loss of CD4 T cells with plasma levels of both soluble form Fas (CD95) Fas ligand (FasL) in HIV-infected infants. Clin Immunol 95(1 Pt 1):20–25PubMedCrossRef

15.

Balasubramanian A, Koziel M, Groopman JE, Ganju RK (2005) Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV. Clin Infect Dis 41(Suppl 1):S32–S37PubMedCrossRef

16.

Dockrell DH (2003) The multiple roles of Fas ligand in the pathogenesis of infectious diseases. Clin Microbiol Infect 9(8):766–779PubMedCrossRef

17.

Volkmann X, Fischer U, Bahr MJ, Ott M, Lehner F, Macfarlane M, Cohen GM, Manns MP, Schulze-Osthoff K, Bantel H (2007) Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 46(5):1498–1508PubMedCrossRef

18.

Melendez MM, McNurlan MA, Mynarcik DC, Khan S, Gelato MC (2008) Endothelial adhesion molecules are associated with inflammation in subjects with HIV disease. Clin Infect Dis 46(5):775–780PubMedCrossRef

19.

Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S (2002) Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 51(9):1143–1147PubMedCrossRef

20.

Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, Hillon P, Portier H (2001) Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 27(3):245–250PubMedCrossRef

21.

Torti C, Patroni A, Tinelli C, Sleiman I, Quiros-Roldan E, Puoti M, Castelli F (2002) Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 29(3):315–317PubMed

22.

Negro F, Sanyal AJ (2009) Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 29(Suppl 2):26–37PubMedCrossRef

23.

Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC (2009) Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 49(2):225–232PubMedCrossRef

24.

Kotler DP (2009) Hepatitis C, human immunodeficiency virus and metabolic syndrome: interactions. Liver Int 29(Suppl 2):38–46PubMedCrossRef

25.

Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M (2010) Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 11(7):462–468PubMed

26.

Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J (2001) Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104(12):1336–1342PubMedCrossRef

27.

Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Hérnandez G, Egido J (2007) Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol 27(1):168–174PubMedCrossRef

28.

Martín-Ventura JL, Blanco-Colio LM, Muñoz-García B, Gómez-Hernández A, Arribas A, Ortega L, Tuñón J, Egido J (2004) NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability. Stroke 35(2):458–463PubMedCrossRef

29.

Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P (1997) Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17(10):2200–2208PubMedCrossRef

30.

Berenguer J, Bellón JM, Miralles P, Alvarez E, Sánchez-Conde M, Cosín J, López JC, Alvarez F, Catalán P, Resino S (2007) Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 14(12):859–869PubMed

31.

Hayashi N, Mita E (1997) Fas system and apoptosis in viral hepatitis. J Gastroenterol Hepatol 12(9–10):S223–S226PubMedCrossRef

32.

Lapinski TW, Jaroszewicz J, Wiercinska-Drapalo A (2006) Concentrations of soluble Fas and soluble Fas ligand as indicators of programmed cell death among patients coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. Viral Immunol 19(3):570–575PubMedCrossRef

33.

Herbein G, Khan KA (2008) Is HIV infection a TNF receptor signalling-driven disease? Trends Immunol 29(2):61–67PubMedCrossRef

34.

Moanna A, Dunham R, Paiardini M, Silvestri G (2005) CD4+ T-cell depletion in HIV infection: killed by friendly fire? Curr HIV/AIDS Rep 2(1):16–23PubMedCrossRef

35.

Capa L, Soriano V, García-Samaniego J, Nuñez M, Romero M, Cascajero A, Muñoz F, González-Lahoz J, Benito JM (2007) Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus. J Med Virol 79(5):503–510PubMedCrossRef

36.

Cardin R, Saccoccio G, Masutti F, Bellentani S, Farinati F, Tiribelli C (2001) DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. J Hepatol 34(4):587–592PubMedCrossRef

37.

Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU (2007) Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 46(5):1350–1356PubMedCrossRef

38.

Cosson E, Bringuier AF, Paries J, Guillot R, Vaysse J, Attali JR, Feldmann G, Valensi P (2005) Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance. Diabetes Metab 31(1):47–54PubMedCrossRef

39.

Xu C, Lee S, Singh TM, Sho E, Li X, Sho M, Masuda H, Zarins CK (2001) Molecular mechanisms of aortic wall remodeling in response to hypertension. J Vasc Surg 33(3):570–578PubMedCrossRef

40.

Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M (2002) Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 185(4):456–462PubMedCrossRef

41.

Ryan P, Berenguer J, Michelaud D, Miralles P, Bellón JM, Alvarez E, Catalán P, Sánchez-Conde M, Resino S (2009) Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 50(1):109–110PubMedCrossRef

42.

Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW, Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J, Wannamethee SG (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371(9628):1927–1935PubMedCrossRef

43.

Park K, Steffes M, Lee DH, Himes JH, Jacobs DR Jr (2009) Association of inflammation with worsening HOMA-insulin resistance. Diabetologia 52(11):2337–2344PubMedCrossRef

44.

Lecube A, Hernández C, Genescà J, Simó R (2006) Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case–control study. Diabetes Care 29(5):1096–1101PubMedCrossRef

45.

Marín-Serrano E, Rodríguez-Ramos C, Díaz F, Martín-Herrera L, Girón-González JA (2006) Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J Viral Hepat 13(4):230–234PubMedCrossRef

Titel: Soluble Fas and Fas ligand in HIV/HCV coinfected patients and impact of HCV therapy
verfasst von: M. Guzmán-Fulgencio
J. Berenguer
M. García-Álvarez
D. Micheloud
J. C. López
J. Cosín
I. Fernández de Castro
P. Catalán
P. Miralles
S. Resino
Publikationsdatum: 01.10.2011
Verlag: Springer-Verlag
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 10/2011
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-011-1215-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2011

Q fever seroprevalence in metropolitan samples is similar to rural/remote samples in Queensland, Australia

Differentiating the growing nosocomial infectious threats Ralstonia pickettii and Ralstonia insidiosa

Host, pathogen and treatment-related prognostic factors in rickettsioses

Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers

Pulsed-field gel electrophoresis characterization of Bordetella pertussis clinical isolates circulating in Turkey in 2001–2009